Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
| Status: | Completed |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | January 2014 |
| End Date: | March 2016 |
| Contact: | Yilei Mao, MD |
| Email: | yileimao@126.com |
| Phone: | 13011079603 |
Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.
Circulating free cell DNA (cfDNA) is extracellular fragmentation of nucleic acids that
occurs both in plasma and serum. This kind of DNA which derived from the apoptotic/necrotic
cells or the lysis of circulating tumor cells (CTCs) can be detectedin the patients with a
variety of diseases. Emerging evidence suggests that cfDNA from patients exhibits
characteristicchanges of tumors, suchas mutations, insertions/deletions,
methylations,microsatellite aberrations, and copy number variations, etc. All of these
reveal a visible difference between the benign conditions, and thus may be useful in the
diagnosis of cancer, identification of targeted therapy, monitor responses to treatments,
and early detection of relapse. The purpose for this study is to explore these
characteristic changes in the patients withhepatocellular carcinoma (HCC) and expect to
guide targeted therapy and identify non-invasive biomarkers of cancer diagnosis and
prognosis which can be easily isolated from the circulation.
occurs both in plasma and serum. This kind of DNA which derived from the apoptotic/necrotic
cells or the lysis of circulating tumor cells (CTCs) can be detectedin the patients with a
variety of diseases. Emerging evidence suggests that cfDNA from patients exhibits
characteristicchanges of tumors, suchas mutations, insertions/deletions,
methylations,microsatellite aberrations, and copy number variations, etc. All of these
reveal a visible difference between the benign conditions, and thus may be useful in the
diagnosis of cancer, identification of targeted therapy, monitor responses to treatments,
and early detection of relapse. The purpose for this study is to explore these
characteristic changes in the patients withhepatocellular carcinoma (HCC) and expect to
guide targeted therapy and identify non-invasive biomarkers of cancer diagnosis and
prognosis which can be easily isolated from the circulation.
In cancer, cfDNA can be detected a higher concentration in the circulation because of the
necrosis of neoplasm cells with the rapid enlargement and relatively shortage of blood
supply. So, identifying tumor-specific genetic and epigenetic changes in cfDNA on this
status, such as gene mutations, deletions, methylation alterations and microsatellite
alterations, may be more specific for us to diagnose the neoplasms in early phase. This
phenomenon also appears in the patients with hepatocellular carcinoma (HCC). Studies have
shown that cfDNA level is associated with intrahepatic and extrahepatic metastasis in HCC
patients and examined some cfDNAcharacteristic changes, such as p161NK4A, RTL, RASSF1A,
LINE-1 and GSTP1. Thus is useful for us to explore the specific cfDNA in HCC. For a high
sensitivity and specificity detection, we will use technologiesdeveloped at Stanford Genome
Technology Centerto find more characteristic gene mutations, methylation alterations or
other changes (3). In this study, we willinvestigate thesecharacteristic changesin cfDNA and
primary tumor lesions.
Study arrangement:
Collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients
with HCC.
Detect the DNA sequence from the samples of plasma, blood cells and solid tumor tissues.
Identify cancer specific variations in cfDNA and primary tumor lesions. Date analysis and
investigate these characteristic changes. Evaluate the application in early diagnosis,
treatment monitoring and prognosis for HCC.
necrosis of neoplasm cells with the rapid enlargement and relatively shortage of blood
supply. So, identifying tumor-specific genetic and epigenetic changes in cfDNA on this
status, such as gene mutations, deletions, methylation alterations and microsatellite
alterations, may be more specific for us to diagnose the neoplasms in early phase. This
phenomenon also appears in the patients with hepatocellular carcinoma (HCC). Studies have
shown that cfDNA level is associated with intrahepatic and extrahepatic metastasis in HCC
patients and examined some cfDNAcharacteristic changes, such as p161NK4A, RTL, RASSF1A,
LINE-1 and GSTP1. Thus is useful for us to explore the specific cfDNA in HCC. For a high
sensitivity and specificity detection, we will use technologiesdeveloped at Stanford Genome
Technology Centerto find more characteristic gene mutations, methylation alterations or
other changes (3). In this study, we willinvestigate thesecharacteristic changesin cfDNA and
primary tumor lesions.
Study arrangement:
Collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients
with HCC.
Detect the DNA sequence from the samples of plasma, blood cells and solid tumor tissues.
Identify cancer specific variations in cfDNA and primary tumor lesions. Date analysis and
investigate these characteristic changes. Evaluate the application in early diagnosis,
treatment monitoring and prognosis for HCC.
Inclusion Criteria:
Age≥18years and ≤80 years; Histologically and cytologically proven Hepatocellular
carcinoma Child-Pugh：child A-B Adequate hematological, renal, cardiac and pulmonary
functions Tumor in any segment of liver
Exclusion Criteria:
Uncontrolled systemic disease Reject the surgical treatment Metastatic carcinoma
Child-Pugh：child C
We found this trial at
1
site
Click here to add this to my saved trials
